News

23 Jun 2026

PExA signs agreement with global pharmaceutical company for 10 instruments for clinical multicenter study in pulmonary fibrosis, with a value of approximately SEK 7.5 million

News, Press Releases

PExA AB has signed an agreement with one of the world’s ten largest pharmaceutical companies regarding the delivery, installation and rental of ten PExA 2.1 systems for use in an international clinical study in idiopathic pulmonary fibrosis (IPF). Under the agreement, the customer will rent ten systems for a period of 18 months. The total…

10 Jun 2026

U.S. government agency customer orders upgrade of existing PExA system

News, Press Releases

PExA AB has received an order from a U.S. government agency customer, which is one of the world’s largest public funders of medical research, for the upgrade of an existing PExA 2.1 system. The upgrade adds new functionality intended to simplify and improve the efficiency of sample collection and sample handling in the customer’s research…

02 Jun 2026

New doctoral thesis strengthens PExA’s opportunities in lung cancer and other lung diseases

News, Press Releases

A new doctoral thesis from Lund University, entirely based on PExA’s technology for analysing exhaled particles from the lungs, strengthens the view of PExA as a platform for non-invasive biomarker analysis. The thesis shows how PExA-based breath samples can provide biologically relevant information across four different areas of lung disease: infection/COVID-19, lung transplantation, acute lung…

25 May 2026

TV4 News highlights research where PExA’s technology is being used for future early detection of lung cancer

News, Press Releases

During Sunday, Swedish national broadcaster TV4 News featured research where PExA’s technology is being used in several of its national news broadcasts. The report focused on future possibilities for detecting lung diseases such as COPD and lung cancer at an earlier stage through analysis of exhaled air. In the feature, titled “New technology may detect…

13 May 2026

PExA partner in Dutch precision medicine project within COPD and interstitial lung diseases

News, Press Releases

PExA has become an industrial partner in the Dutch research project COPD-PARASOL-ILD, which forms part of the national precision medicine initiative P4O2. The project aims to identify and validate biomarkers for improved diagnosis and treatment monitoring in chronic lung diseases such as COPD and interstitial lung disease (ILD). Other partners in the project are amongst…